Future Financial Wealth Managment LLC Lowers Position in Viking Therapeutics, Inc. $VKTX

Future Financial Wealth Managment LLC reduced its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 42.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,350 shares of the biotechnology company’s stock after selling 1,000 shares during the period. Future Financial Wealth Managment LLC’s holdings in Viking Therapeutics were worth $36,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in VKTX. Quarry LP grew its position in shares of Viking Therapeutics by 1,621.4% in the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,135 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 536 shares during the last quarter. NBC Securities Inc. grew its holdings in shares of Viking Therapeutics by 222,100.0% during the first quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 2,221 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Viking Therapeutics by 571.4% during the second quarter. Farther Finance Advisors LLC now owns 2,041 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,737 shares during the last quarter. Finally, JNBA Financial Advisors purchased a new position in shares of Viking Therapeutics during the first quarter worth about $56,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VKTX has been the topic of a number of research reports. Raymond James Financial dropped their price target on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating on the stock in a research note on Thursday, July 24th. HC Wainwright restated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Monday, September 29th. Citigroup raised their target price on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. BTIG Research restated a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a research report on Monday, September 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $86.42.

Viking Therapeutics Trading Up 6.6%

Shares of VKTX stock opened at $29.72 on Friday. The business’s 50 day moving average is $29.30 and its two-hundred day moving average is $27.92. Viking Therapeutics, Inc. has a twelve month low of $18.92 and a twelve month high of $81.73. The company has a market capitalization of $3.34 billion, a P/E ratio of -19.42 and a beta of 0.64.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). During the same quarter in the previous year, the firm posted ($0.20) EPS. Viking Therapeutics’s revenue for the quarter was up NaN% on a year-over-year basis. As a group, equities analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.